Tuesday's Health Winners & Losers

Nuerochem(NRMX) shed another 26% Tuesday, while investors responded more enthusiastically to news from other health stocks.

Neurochem issued a statement Tuesday saying it had about $80 million in cash as of July 31. The biopharmaceutical company said its cash reserves should support current operations for 15 to 18 months, but recommendations of the special advisory board for Alzhemed and other upcoming milestone events make it impossible to predict its cash requirements.

On Monday the stock tumbled 40% when the company announced that results from its phase III trial on Alzheimer's disease treatment Alzhemed didn't demonstrate a statistically significant difference in favor of the drug. Neurochem is a component of the Nasdaq biotechnology index, which was down 9.4, or 1.2%, to 792.63.

On the winning side Tuesday, Omrix Biopharmacueticals(OMRI) gained $4.89, or 16.8%, to $33.96, after the FDA announced that it approved Evithrom, a blood-clotting agent used during surgery that will be manufactured by Omrix and distributed by Johnson & Johnson(JNJ). J&J edged down 35 cents, to $61.25.

Laser developer Candela(CLZR) said Tuesday that it received additional FDA clearance for its Serenity device to reduce pain during laser and intense pulse light treatments.

The device uses pneumatic skin flattening (PSF) technology, which Candela obtained through the acquisition of Israel-based Inolase last March. Shares climbed 4.5%, to $7.70.